Clinical trial
Lanreotide (Somatuline Autogel) in Thyroid-associated Ophthalmopathy Treatment
NCT00288522 · Ipsen, Industry · Terminated
Key facts
| NCT number | NCT00288522 |
|---|---|
| Title | Lanreotide (Somatuline Autogel) in Thyroid-associated Ophthalmopathy Treatment |
| Official title | A Phase II, Single Centre, Randomized, Double-blind, Parallel and Placebo Controlled, Pilot Study to Evaluate the Efficacy and Safety of Somatuline Autogel 60mg in Patients With Active Thyroid-associated Ophthalmopathy of Moderate Intensity. |
| Lead sponsor | Ipsen, Industry |
| Status | Terminated |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Thyroid-Associated Ophthalmopathy |
| Intervention type | Drug |
| Interventions | Lanreotide (Autogel formulation). Duration of treatment - 3 injections, 1 every 28 days |
| Enrollment | 5 |
| Start date | Jan 1, 2006 |
| Primary completion | Apr 1, 2007 |
| Completion | Apr 1, 2007 |
| First posted | Feb 8, 2006 |
| Last update posted | Jun 2, 2020 |
| Countries | Spain |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: